5.2 Formulating Etiology-Directed and Comorbidity-Integrated Goals

Quick Overview: Heart failure management cannot follow a one-size-fits-all paradigm. Formulating an individualized care plan requires tailoring goals of care to the underlying cardiomyopathy etiology—whether ischemic, genetic, toxic, or obstructive—while seamlessly integrating complex comorbidities. The certified heart failure nurse must recognize critical disease-specific pharmacological caveats, such as avoiding arterial vasodilators in obstructive hypertrophic cardiomyopathy, avoiding adaptive servoventilation in central sleep apnea with HFrEF, tolerating benign hemodynamic eGFR declines in chronic kidney disease, and utilizing novel potassium binders to maintain guideline-directed medical therapy.

---

Etiology-Directed Care Planning

┌─────────────────────────────────────────────────────────────────────────────┐
│                     Etiology-Directed Care Plan Matrix                      │
├──────────────────────────┬──────────────────────────────────────────────────┤
│ Underlying Etiology      │ Mandated Clinical Interventions & Nursing Focus  │
├──────────────────────────┼──────────────────────────────────────────────────┤
│ Ischemic Cardiomyopathy  │ • High-intensity statin (atorvastatin 40-80 mg or│
│                          │   rosuvastatin 20-40 mg) to achieve ≥50% LDL drop│
│                          │ • Antiplatelet therapy (aspirin, DAPT post-PCI)  │
│                          │ • Heart-team review for revascularization        │
│                          │   (CABG survival benefit in STICH/STICHES)       │
│                          │ • Aggressive surveillance for recurrent ischemia │
├──────────────────────────┼──────────────────────────────────────────────────┤
│ Non-Ischemic Dilated     │ • 3-generation family pedigree & genetic testing │
│ Cardiomyopathy (DCM)     │   (LMNA, TTN, FLNC, RBM20 mutations)             │
│                          │ • Complete abstinence from cardiotoxins (alcohol,│
│                          │   cocaine, methamphetamine)                      │
│                          │ • Holter surveillance for malignant arrhythmias  │
│                          │ • Family screening: 1st-degree relatives every   │
│                          │   3-5 years with ECG and echocardiography        │
├──────────────────────────┼──────────────────────────────────────────────────┤
│ Hypertrophic Cardio-     │ • First-line: Non-vasodilating beta-blockers or  │
│ myopathy (Obstructive    │   non-DHP CCBs (verapamil, diltiazem)            │
│ HCM / HOCM)              │ • CONTRAINDICATED: Arterial vasodilators (DHP    │
│                          │   CCBs, hydralazine, nitrates) & high-dose       │
│                          │   diuretics that worsen LVOT obstruction & SAM   │
│                          │ • Mavacamten (myosin inhibitor) under REMS:      │
│                          │   echo monitoring; hold if LVEF <50%             │
└──────────────────────────┴──────────────────────────────────────────────────┘

1. Ischemic Cardiomyopathy

In ischemic heart failure, care planning revolves around secondary prevention, plaque stabilization, and revascularization of viable, hibernating myocardium:

• Lipid-Lowering Therapy: High-intensity statin therapy (atorvastatin 40–80 mg or rosuvastatin 20–40 mg daily) is prescribed with a target LDL-C reduction of ≥ 50% and an absolute LDL-C goal <55-70 mg/dL. If targets are unmet, ezetimibe and PCSK9 inhibitors are added.
• Antiplatelet Therapy: Aspirin 81 mg daily indefinitely. In patients with acute coronary syndromes or recent percutaneous coronary intervention (PCI), dual antiplatelet therapy (DAPT) with aspirin plus a P2Y₁₂ inhibitor (clopidogrel, ticagrelor) is maintained for 6 to 12 months based on stent type and bleeding risk.
• Coronary Revascularization & Viability: The landmark STICH (Surgical Treatment for Ischemic Heart Failure) trial and its 10-year STICHES extension demonstrated that coronary artery bypass grafting (CABG) combined with medical therapy significantly reduced 10-year all-cause mortality compared to medical therapy alone in patients with LVEF ≤ 35% and coronary disease suitable for CABG. Viability testing (cardiac MRI, 18F-FDG PET, or dobutamine stress echocardiography) can identify hibernating myocardium, but in the STICH viability substudy it did not identify which patients gained survival benefit from CABG, and REVIVED-BCIS2 found that PCI did not reduce death or HF hospitalization in ischemic LV dysfunction. The heart team individualizes revascularization decisions.

2. Non-Ischemic Dilated Cardiomyopathy (DCM)

• Genetic Evaluation: Up to 30-40% of non-ischemic DCM cases have an identifiable genetic origin. Truncating variants in the titin gene (TTN) are the most common. Crucially, mutations in the lamin A/C gene (LMNA) carry a malignant propensity for atrioventricular block, sustained ventricular tachycardia, and sudden cardiac death out of proportion to ejection fraction reduction, often justifying early ICD implantation before the standard LVEF ≤ 35% threshold is reached.
• Toxin Cessation: Alcoholic cardiomyopathy requires absolute, permanent abstinence. Toxin-induced myocardial injury can show remarkable reverse remodeling and normalization of ejection fraction over 3 to 12 months with abstinence and GDMT.

3. Hypertrophic Cardiomyopathy (HCM)

• Hemodynamic Trap: In hypertrophic obstructive cardiomyopathy (HOCM), asymmetric septal hypertrophy coupled with systolic anterior motion (SAM) of the mitral valve creates dynamic left ventricular outflow tract (LVOT) obstruction.
• Strictly Contraindicated Agents: Pure arterial vasodilators (dihydropyridine calcium channel blockers like amlodipine, hydralazine, oral nitrates, and PDE-5 inhibitors) decrease systemic vascular resistance, reducing ventricular filling and exacerbating the outflow gradient. High-dose diuretics cause hypovolemia and chamber underfilling, which pulls the mitral leaflet into the septum, worsening dynamic obstruction.
• First-Line Pharmacotherapy: Non-vasodilating beta-blockers titrated to a resting heart rate of ~60 bpm prolong diastolic filling and reduce mechanical obstruction. Non-dihydropyridine calcium channel blockers (verapamil, diltiazem) are second-line alternatives.
• Mavacamten Monitoring: Mavacamten is a first-in-class cardiac myosin ATPase inhibitor that reversibly inhibits excess actin-myosin cross-bridging, reducing hypercontractility and abolishing LVOT gradients. Because excessive inhibition can depress systolic function, it is prescribed under a strict Risk Evaluation and Mitigation Strategies (REMS) program. Treatment starts only when LVEF is ≥ 55%, and echocardiograms are repeated on the schedule set by the REMS program and product labeling during titration and at regular intervals afterward. The drug must be temporarily withheld if LVEF drops <50% or if the patient develops severe intercurrent clinical illness.

---

Comorbidity Integration in Heart Failure Care Plans

1. Diabetes Mellitus

• SGLT2 Inhibitors as Foundational GDMT: Dapagliflozin and empagliflozin are foundational GDMT in HFrEF (Class 1) and recommended in HFmrEF and HFpEF (Class 2a), regardless of diabetes status. In diabetic patients, they provide glycemic control with a negligible risk of hypoglycemia while reducing cardiovascular death and heart failure hospitalization by 25-30%.
• Strictly Contraindicated: Thiazolidinediones (TZDs): Pioglitazone and rosiglitazone stimulate peroxisome proliferator-activated receptor gamma (PPAR-γ) in the renal collecting ducts, causing vigorous renal sodium and water reabsorption. In clinical trials, TZDs doubled the rate of heart failure decompensation and hospital admissions (Class III: Harm).
• Sulfonylurea Precautions: Sulfonylureas (glimepiride, glipizide) carry substantial risks of severe hypoglycemia, especially when renal perfusion fluctuates during diuresis. Metformin is safe in stable chronic heart failure but must be withheld in acute decompensation, hypoperfusion, or when eGFR <30 mL/min/1.73m² due to lactic acidosis risk.

2. Chronic Kidney Disease (CKD) & Cardiorenal Syndrome

• Managing the Benign Hemodynamic eGFR Dip: Initiating or up-titrating ACE inhibitors, ARBs, ARNIs, or SGLT2 inhibitors regularly causes an acute, transient reduction in eGFR of up to 20-30%.
  • Mechanism: SGLT2 inhibitors constrict the afferent arteriole via tubuloglomerular feedback; RAAS inhibitors dilate the efferent arteriole. Both actions lower intraglomerular capillary hypertension, protecting long-term nephron survival.
  • Action: An initial eGFR drop ≤ 30% is an expected hemodynamic adjustment, not acute tubular necrosis. The nurse should advocate to continue therapy unless the eGFR drop exceeds 30%, oliguria occurs, or refractory hyperkalemia ensues.
• Novel Potassium Binders: Hyperkalemia (K⁺ >5.0-5.5 mEq/L) historically forced the discontinuation of life-saving RAAS inhibitors and mineralocorticoid receptor antagonists (MRAs; spironolactone, eplerenone). Modern heart failure practice utilizes non-absorbed oral potassium binders:
  • Patiromer: Binds potassium in exchange for calcium in the distal colon.
  • Sodium Zirconium Cyclosilicate (SZC / Lokelma): Highly selective inorganic crystal that traps potassium in exchange for sodium throughout the entire gastrointestinal tract, acting within 1 to 2 hours.
  • Clinical Goal: Utilize potassium binders to enable the continuation and target-dose titration of RAASi and MRAs, rather than discontinuing foundational GDMT.

             ┌────────────────────────────────────────────────────────┐
             │ Cardiorenal Preservation Algorithm in Heart Failure    │
             └───────────────────────────┬────────────────────────────┘
                                         │
                 ┌───────────────────────┴───────────────────────┐
                 ▼                                               ▼
      ┌─────────────────────┐                         ┌─────────────────────┐
      │ Initiation of ARNI, │                         │ Potassium Rises to  │
      │ ACEi, or SGLT2i     │                         │ 5.1 - 5.9 mEq/L     │
      └──────────┬──────────┘                         └──────────┬──────────┘
                 ▼                                               ▼
      ┌─────────────────────┐                         ┌─────────────────────┐
      │ Serum Creatinine    │                         │ DO NOT Discontinue  │
      │ Rises / eGFR Drops  │                         │ MRA / RAASi!        │
      └──────────┬──────────┘                         └──────────┬──────────┘
                 │                                               │
         ┌───────┴───────┐                                       ▼
         ▼               ▼                            ┌─────────────────────┐
┌────────────────┐ ┌────────────────┐                 │ Initiate Oral       │
│ Decline ≤30%:  │ │ Decline >30%:  │                 │ Potassium Binder    │
│ Benign effect. │ │ Evaluate hypov │                 │ (Patiromer / SZC);  │
│ Continue GDMT. │ │ olemia; adjust │                 │ Maintain Life-Saving│
│ Recheck in 2-4 │ │ loop diuretic. │                 │ Neurohormonal Block │
│ weeks.         │ │                │                 └─────────────────────┘
└────────────────┘ └────────────────┘

3. Chronic Obstructive Pulmonary Disease (COPD)

• Diagnostic Confirmation: Because "cardiac asthma" (pulmonary interstitial edema causing wheezing) mimics chronic bronchitis or reactive airway bronchospasm, objective spirometry demonstrating a post-bronchodilator FEV₁/FVC <0.70 is required to confirm true airflow obstruction, supported by natriuretic peptides (BNP / NT-proBNP).
• Safety of Cardioselective Beta-1 Blockers: A widespread clinical misconception is that beta-blockers are contraindicated in COPD. Evidence, including meta-analyses of randomized trials, shows that cardioselective beta-1 blockers (metoprolol succinate, bisoprolol) do not meaningfully worsen lung function or respiratory symptoms, so their mortality benefit in HFrEF should not be withheld. Beta-blockers must never be withheld from heart failure patients simply due to a diagnosis of COPD. Non-selective beta-blockers (such as carvedilol, which blocks beta-1, beta-2, and alpha-1 receptors) can be used in stable mild COPD, but cardioselective agents are preferred in patients with severe airway hyperreactivity or asthma.

4. Atrial Fibrillation (AFib)

• Rate vs. Rhythm Control: In chronic heart failure, rate control is initial standard therapy (resting heart rate target <80-110 bpm using beta-blockers or digoxin).
  • Contraindication: Non-dihydropyridine calcium channel blockers (diltiazem, verapamil) are strictly contraindicated in HFrEF due to negative inotropic effects leading to acute cardiogenic decompensation.
  • Rhythm Control Indications: Rhythm control (catheter ablation or cardioversion) is indicated for patients with persistent symptoms, tachycardia-induced cardiomyopathy, or acute instability. The CASTLE-AF trial found that catheter ablation reduced the composite of death or HF hospitalization in selected patients with HFrEF, and the 2022 guideline rates AF ablation as reasonable (Class 2a) when it is expected to improve symptoms or LV function.
  • Antiarrhythmic Safety: Class I antiarrhythmics (flecainide, propafenone) are contraindicated due to proarrhythmic mortality risks demonstrated in the CAST trial. Only amiodarone and dofetilide are proven safe in HFrEF.
• Stroke Prevention: Direct Oral Anticoagulants (DOACs: apixaban, rivaroxaban, edoxaban, dabigatran) are preferred over warfarin (except with mechanical valves or moderate-to-severe mitral stenosis) because of lower intracranial hemorrhage rates and predictable pharmacokinetics. Chronic anticoagulation is recommended when the CHA₂DS₂-VASc score is ≥ 2 in men or ≥ 3 in women; heart failure itself contributes 1 point.

5. Sleep-Disordered Breathing

• Screening & Diagnosis: The 2022 guideline rates a formal sleep assessment as reasonable when sleep-disordered breathing or excessive daytime sleepiness is suspected (Class 2a). Tools such as STOP-BANG support screening, and polysomnography confirms the diagnosis and the central-versus-obstructive pattern (for example, AHI ≥ 15 events/hour, or ≥ 5 with symptoms).
• Obstructive Sleep Apnea (OSA): Continuous Positive Airway Pressure (CPAP) is first-line; it reduces nocturnal sympathetic surges, lowers systemic blood pressure, and improves quality of life.
• Central Sleep Apnea (CSA) with Cheyne-Stokes Breathing: Extremely prevalent in advanced HFrEF (30-50%), driven by hyperventilation and altered central chemoreceptor sensitivity.
• CRITICAL CONTRAINDICATION: Adaptive Servoventilation (ASV): The multicenter SERVE-HF randomized trial evaluated ASV in patients with symptomatic HFrEF (LVEF ≤ 45%) and predominant CSA. ASV produced a statistically significant increase in all-cause mortality (HR 1.28) and cardiovascular mortality (HR 1.34). Consequently, ASV is strictly contraindicated (Class III: Harm) in HFrEF with central sleep apnea.

---

Clinical Case Scenario: Navigating Complex Comorbidities

A 65-year-old male with chronic ischemic cardiomyopathy (LVEF 28%), type 2 diabetes mellitus, and chronic kidney disease stage 3b (eGFR 36 mL/min/1.73m², serum creatinine 1.8 mg/dL, potassium 4.7 mEq/L) is evaluated in the outpatient heart failure clinic. He complains of daytime somnolence and loud snoring. His current medications include carvedilol 25 mg twice daily, sacubitril/valsartan 24/26 mg twice daily, and furosemide 40 mg daily.

• Clinical Decisions & Adjustments:
  1. To optimize the four pillars of GDMT, the nurse advocates initiating empagliflozin 10 mg daily. At a 10-day laboratory check, the patient's creatinine increases to 2.0 mg/dL and eGFR drops to 32 mL/min/1.73m² (an 11% decline), while his serum potassium rises to 5.3 mEq/L. The patient is clinically euvolemic with clear lungs and no edema.
  2. Recognizing this 11% eGFR decline as a benign, expected hemodynamic reduction in intraglomerular pressure, the nurse reassures the team and continues the SGLT2 inhibitor and ARNI.
  3. To manage the potassium of 5.3 mEq/L and enable future initiation of spironolactone, the team starts the oral potassium binder patiromer 8.4 g daily, maintaining GDMT rather than stopping neurohormonal blockade.
  4. Polysomnography reveals an AHI of 32 with 90% obstructive events. The patient is safely fitted for CPAP. The nurse ensures that adaptive servoventilation (ASV) is explicitly avoided on the prescription orders due to his reduced ejection fraction.

---

CHFN Exam Traps & Clinical Pearls

[!WARNING] Exam Trap: The SERVE-HF trial finding is a high-yield exam question! Adaptive Servoventilation (ASV) is strictly CONTRAINDICATED in patients with symptomatic HFrEF (LVEF ≤ 45%) and predominant central sleep apnea because it significantly increases cardiovascular mortality. If an exam question asks for the appropriate therapy for central sleep apnea in HFrEF, optimizing GDMT is the correct answer—never ASV!

[!IMPORTANT] Clinical Pearl: When initiating ACEi, ARB, ARNI, or SGLT2i, a serum creatinine rise up to 30% (or eGFR drop up to 30%) from baseline is expected and acceptable. Do NOT discontinue therapy unless the decline exceeds 30% or severe intractable hyperkalemia occurs.

[!TIP] Exam Trap: Never use non-dihydropyridine calcium channel blockers (diltiazem or verapamil) for rate control of atrial fibrillation in patients with HFrEF. Their potent negative inotropic properties can precipitate cardiogenic shock and worsen decompensation.